Analytical Data
-
Gene name
S100A8
- Application
-
Alternative Names
MRP8; MIF; 60B8AG; CAGA; CFAG; CGLA; CP-10; L1Ag; NIF; P8; Calgranulin A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8
-
Species
Mouse
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P27005
-
Expression Region
Met1~Glu89
-
Molecular Weight
10kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Azurocidin, also known as AZU or human neutrophil peptide 1 (HNP-1), is a cationic antimicrobial protein predominantly found in neutrophils, playing a crucial role in the innate immune response. Its primary functions include microbial killing, modulation of inflammation, and wound healing. The interest in recombinant Azurocidin has surged due to its potential therapeutic applications, particularly in the treatment of infections caused by multidrug-resistant bacteria. Research indicates that Azurocidin exhibits a broad spectrum of antibacterial activity against Gram-positive and Gram-negative pathogens, making it a promising candidate for developing new antimicrobial agents. Furthermore, its role in recruiting and activating immune cells suggests that it could also be a valuable tool in enhancing immune responses in patients with immune deficiencies. The recombinant production of Azurocidin allows for the generation of large quantities of pure protein, facilitating detailed structural and functional studies and paving the way for future clinical applications. As antibiotic resistance remains a pressing global health challenge, the exploration of Azurocidin as a novel therapeutic option is a timely and significant area of research that can contribute toward effective infection control strategies.
